Nippon Chemiphar Co., Ltd. (4539.T)
JPY 1438.0
(0.14%)
JPY 1438.0
(0.14%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -180 Million JPY | -153.1% |
| 2022 | 339 Million JPY | -51.57% |
| 2021 | 700 Million JPY | 41.41% |
| 2020 | 495 Million JPY | 13.53% |
| 2019 | 436 Million JPY | -50.51% |
| 2018 | 881 Million JPY | -24.05% |
| 2017 | 1.16 Billion JPY | -43.52% |
| 2016 | 2.05 Billion JPY | 4.74% |
| 2015 | 1.96 Billion JPY | 3.26% |
| 2014 | 1.89 Billion JPY | 0.64% |
| 2013 | 1.88 Billion JPY | -11.2% |
| 2012 | 2.12 Billion JPY | 47.67% |
| 2011 | 1.43 Billion JPY | 151.13% |
| 2010 | 573 Million JPY | 112.22% |
| 2009 | 270 Million JPY | 60.71% |
| 2008 | 168 Million JPY | -56.92% |
| 2007 | 390 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -170 Million JPY | -234.92% |
| 2024 Q1 | 126 Million JPY | 144.37% |
| 2023 FY | -180 Million JPY | -153.1% |
| 2023 Q3 | 73 Million JPY | 252.08% |
| 2023 Q2 | -48 Million JPY | -160.76% |
| 2023 Q1 | 79 Million JPY | 122.9% |
| 2023 Q4 | -284 Million JPY | -489.04% |
| 2022 FY | 339 Million JPY | -51.57% |
| 2022 Q1 | 653 Million JPY | 359.13% |
| 2022 Q4 | -345 Million JPY | -62.74% |
| 2022 Q2 | 243 Million JPY | -62.79% |
| 2022 Q3 | -212 Million JPY | -187.24% |
| 2021 Q4 | -252 Million JPY | -134.81% |
| 2021 Q1 | -13 Million JPY | -108.13% |
| 2021 Q2 | 241 Million JPY | 1953.85% |
| 2021 Q3 | 724 Million JPY | 200.41% |
| 2021 FY | 700 Million JPY | 41.41% |
| 2020 Q3 | 592 Million JPY | 314.49% |
| 2020 Q4 | 160 Million JPY | -72.97% |
| 2020 FY | 495 Million JPY | 13.53% |
| 2020 Q1 | 19 Million JPY | 108.23% |
| 2020 Q2 | -276 Million JPY | -1552.63% |
| 2019 Q1 | 420 Million JPY | 740.0% |
| 2019 FY | 436 Million JPY | -50.51% |
| 2019 Q2 | -94 Million JPY | -122.38% |
| 2019 Q3 | 341 Million JPY | 462.77% |
| 2019 Q4 | -231 Million JPY | -167.74% |
| 2018 Q2 | 206 Million JPY | -27.72% |
| 2018 Q1 | 285 Million JPY | 329.84% |
| 2018 Q4 | 50 Million JPY | -85.29% |
| 2018 FY | 881 Million JPY | -24.05% |
| 2018 Q3 | 340 Million JPY | 65.05% |
| 2017 Q2 | 322 Million JPY | -21.08% |
| 2017 Q1 | 408 Million JPY | 11.48% |
| 2017 FY | 1.16 Billion JPY | -43.52% |
| 2017 Q4 | -124 Million JPY | -122.38% |
| 2017 Q3 | 554 Million JPY | 72.05% |
| 2016 Q2 | 360 Million JPY | -22.08% |
| 2016 Q4 | 366 Million JPY | -57.74% |
| 2016 FY | 2.05 Billion JPY | 4.74% |
| 2016 Q3 | 866 Million JPY | 140.56% |
| 2016 Q1 | 462 Million JPY | 32.38% |
| 2015 Q4 | 349 Million JPY | -52.45% |
| 2015 FY | 1.96 Billion JPY | 3.26% |
| 2015 Q3 | 734 Million JPY | 58.53% |
| 2015 Q2 | 463 Million JPY | 11.57% |
| 2015 Q1 | 415 Million JPY | 284.26% |
| 2014 Q3 | 746 Million JPY | 78.47% |
| 2014 Q4 | 108 Million JPY | -85.52% |
| 2014 FY | 1.89 Billion JPY | 0.64% |
| 2014 Q1 | 627 Million JPY | 320.81% |
| 2014 Q2 | 418 Million JPY | -33.33% |
| 2013 Q3 | 704 Million JPY | 49.15% |
| 2013 Q4 | 149 Million JPY | -78.84% |
| 2013 FY | 1.88 Billion JPY | -11.2% |
| 2013 Q1 | 562 Million JPY | 251.25% |
| 2013 Q2 | 472 Million JPY | -16.01% |
| 2012 Q3 | 622 Million JPY | -8.53% |
| 2012 Q1 | 663 Million JPY | 508.26% |
| 2012 Q4 | 160 Million JPY | -74.28% |
| 2012 FY | 2.12 Billion JPY | 47.67% |
| 2012 Q2 | 680 Million JPY | 2.56% |
| 2011 Q2 | 305 Million JPY | -15.75% |
| 2011 Q3 | 663 Million JPY | 117.38% |
| 2011 Q4 | 109 Million JPY | -83.56% |
| 2011 FY | 1.43 Billion JPY | 151.13% |
| 2011 Q1 | 362 Million JPY | 115.48% |
| 2010 FY | 573 Million JPY | 112.22% |
| 2010 Q3 | 318 Million JPY | 835.29% |
| 2010 Q1 | 53 Million JPY | -10.17% |
| 2010 Q4 | 168 Million JPY | -47.17% |
| 2010 Q2 | 34 Million JPY | -35.85% |
| 2009 Q2 | 15 Million JPY | -51.61% |
| 2009 Q1 | 31 Million JPY | -78.91% |
| 2009 FY | 270 Million JPY | 60.71% |
| 2009 Q4 | 59 Million JPY | -64.24% |
| 2009 Q3 | 165 Million JPY | 1000.0% |
| 2008 Q2 | -20 Million JPY | 0.0% |
| 2008 Q4 | 147 Million JPY | 83.75% |
| 2008 FY | 168 Million JPY | -56.92% |
| 2008 Q3 | 80 Million JPY | 500.0% |
| 2007 FY | 390 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | 105.616% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 100.125% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 99.943% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 100.111% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | 265.2% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 100.696% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 102.243% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 100.424% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | 125.825% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 101.289% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 103.959% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | 113.072% |
| Tsumura & Co. | 16.7 Billion JPY | 101.077% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 101.613% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 104.37% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 101.113% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 105.24% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 102.328% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 103.382% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 96.322% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 105.463% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 90.83% |
| MedRx Co., Ltd | -932 Million JPY | 80.687% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 104.769% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 83.813% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 92.474% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 102.386% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 101.314% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | 69.451% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 100.871% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | 106.109% |